We recently published a list of Top 10 Stocks to Buy According to Sustainable Insight Capital Management. In this article, we ...
Eli Lilly's stock offers high growth potential, driven by GLP-1 therapies and strong R&D efforts. Read why LLY stock is ...
Senator Ron Wyden (D-Oregon) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on February 21st, the Senator disclosed that they had bought between $50,001 and $100,000 ...
Sustainable Insight Capital Management (SICM) focuses on institutional investments, offering both long-only and long-short strategies in public equities.
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and ...
Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...
Investor's Business Daily on MSN1d
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs ShortageHims stock dropped sharply Friday after the U.S. Food and Drug Administration said the shortage of widely-used weight-loss ...
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...
Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...
David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback